期刊
TUMOR BIOLOGY
卷 37, 期 11, 页码 15333-15339出版社
SAGE PUBLICATIONS LTD
DOI: 10.1007/s13277-016-5462-7
关键词
Vimentin; Glioma; Survival; Temozolomide
类别
资金
- Research Special Fund for Public Welfare Industry of Heath [201402008]
- National Key Research and Development Plan [2016YFC0902500]
- National Natural Science Foundation of China [81572701, 81372700]
- National High Technology Research and Development Program (863) [2012AA02A508]
- Special Fund Project of Translational Medicine in the Chinese-Russian Medical Research Center [CR201417]
- Chinese Society of Neuro-oncology, CACA [CSNO-2014-MSD08]
- Natural and Science Foundation of Heilongjiang Province [H201399]
- Science and technology research project of the Education Department of Heilongjiang Province [12511254]
Gliomas are the most common primary intracranial malignant tumors in adults. Surgical resection followed by optional radiotherapy and chemotherapy is the current standard therapy for glioma patients. Vimentin, a protein of intermediate filament family, could maintain the cellular integrity and participate in several cell signal pathways to modulate the motility and invasion of cancer cells. The purpose of the present research was to identify the relationship between vimentin expression and clinical characteristics and detect the prognostic and predictive ability of vimentin in patients with glioma. To determine the expression of vimentin in glioma tissues, paraffin-embedded blocks from glioma patients by surgical resection were obtained and evaluated by immunohistochemistry. To further investigate the association of vimentin expression with survival, we employed mRNA expression of vimentin genes from the Chinese Glioma Genome Atlas (CGGA) and the GSE 16011 dataset. Kaplan-Meier analysis and Cox regression model were used to statistical analysis. We detected positive vimentin straining in 84 % of high-grade compared to 47 % in low-grade glioma patients. Additionally, vimentin mRNA expression was correlated with glioma grade in both CGGA and GSE16011 dataset. Patients with low vimentin expression have longer survival than high expression. In multivariate analysis, vimentin was an independent significant prognostic factor for high-grade glioma patients. We also identified that glioblastoma patients with low vimentin expression had a better response to temozolomide therapy. Vimentin expression has a significant association with tumor grade and overall survival of high-grade glioma patients. Low vimentin expression may benefit from temozolomide therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据